Search results
- 21.15Add to watchlist+0.10 (+0.50%)At close: Mon. May 13, 2024 3:58 PM EDT · Delayed Quote (USD) · Market closed
- Open21.10High21.20Low21.03
- Mkt CapN/AP/E (TTM)8.90Div & Yield1.25 & 5.94%
- Prev. Close21.0452 Wk. Low18.2052 Wk. High22.80
Related stocks
Tissue-type plasminogen activator, short name tPA, is a protein that facilitates the breakdown of blood clots. It acts as an enzyme to convert plasminogen into its active form plasmin, the major enzyme responsible for clot breakdown. It is a serine protease ( EC 3.4.21.68) found on endothelial cells lining the blood vessels.
- PLAT, T-PA, TPA, plasminogen activator, tissue type
Feb 20, 2023 · Tissue plasminogen activator (tPA) is classified as a serine protease (enzymes that cleave peptide bonds in proteins). It is thus one of the essential components of the dissolution of blood clots. Its primary function includes catalyzing the conversion of plasminogen to plasmin, the primary enzyme involved in dissolving blood clots. Recombinant ...
- Talha N. Jilani, Abdul H. Siddiqui
- 2023/02/20
- 2019
Find the latest AT&T Inc. (T-PA) stock quote, history, news and other vital information to help you with your stock trading and investing.
Milestones in the development of tissue-type plasminogen activator (t-PA) as a fibrin-specific thrombolytic agent include: purification of human t-PA from the culture fluid of the Bowes melanoma cell line, elucidation of the molecular basis of fibrin-specific plasminogen activation, first experimental animal models of thrombosis, first patient ...
- D. Collen, H.R. Lijnen
- 2009
Jan 1, 1998 · Tissue plasminogen activator (t-PA) was demonstrated to be effective in the first 3 hours after acute ischemic stroke in a pivotal randomized clinical trial sponsored by the National Institutes of Neurological Disorders and Stroke (NINDS). 1 Questions regarding the safety and efficacy of t-PA in clinical practice still persist, in part because a...
- David Chiu, Derk Krieger, Carlos Villar-Cordova, Scott E. Kasner, Lewis B. Morgenstern, Patti L. Bra...
- 1998
There is evidence that intravenous thrombolysis with t-PA given within 3 hours of stroke onset improves long-term outcome. 1 Appropriately selected patients treated with t-PA had a 30% to 50% greater likelihood of nearly complete functional and neurological recovery relative to placebo-treated control subjects.
Dec 14, 1995 · We performed a randomized, double-blind trial of intravenous recombinant tissue plasminogen activator (t-PA) for ischemic stroke after recent pilot studies suggested that t-PA was...
